Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eisai Co Ltd Phase III trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of redioiodine-refractory differentiated thyroid cancer

Sunday, 2 Feb 2014 10:30pm EST 

Eisai Co Ltd:Says the Phase III SELECT trial of lenvatinib, an investigational selective tyrosine kinase inhibitor with a novel binding mode, the first-in-class of its kind, met its primary endpoint.Says compared to placebo, lenvatinib showed a statistically improvement in progression free survival in patients with radioiodine-refractory differentiated thyroid cancer. 

Company Quote

-0.39 -0.98%
2:38pm EDT